SCHEMBL22080449

SCHEMBL22080449

O=C(O)CCCCCCCCCCCCCCCCCOc1ccc(S(=O)(=O)Nc2ncc(C(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)O)cn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
PKM P14618 1/20 0.43
CA2 P00918 2/20 0.41
FABP1 P07148 2/20 0.41
HDAC1 Q13547 4/20 0.40
TDP1 Q9NUW8 1/20 0.40
ITGB3 P05106 2/20 0.40
ITGA2B P08514 2/20 0.40
HDAC6 Q9UBN7 4/20 0.38
HDAC3 O15379 3/20 0.38
HDAC4 P56524 3/20 0.38
HDAC7 Q8WUI4 3/20 0.38
HDAC2 Q92769 3/20 0.38
HDAC10 Q969S8 3/20 0.38
HDAC11 Q96DB2 3/20 0.38
HDAC8 Q9BY41 3/20 0.38
HDAC9 Q9UKV0 3/20 0.38
HDAC5 Q9UQL6 3/20 0.38
PLA2G4B P0C869 1/20 0.38
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257865 1.00 SMN1; SMN2 (0.43) SMN1; SMN2PKMCA2FABP1HDAC1
SCHEMBL24257978 1.00 SMN1; SMN2 (0.43) SMN1; SMN2PKMCA2FABP1HDAC1
SCHEMBL22029352 1.00 SMN1; SMN2 (0.43) SMN1; SMN2PKMCA2FABP1HDAC1
SCHEMBL24257868 1.00 SMN1; SMN2 (0.43) SMN1; SMN2PKMCA2FABP1HDAC1
SCHEMBL24257864 0.97 SMN1; SMN2 (0.43) SMN1; SMN2PKMCA2FABP1HDAC1
SCHEMBL31682096 0.97 SMN1; SMN2 (0.43) SMN1; SMN2PKMCA2FABP1HDAC1
SCHEMBL24257953 0.96 SMN1; SMN2 (0.40) SMN1; SMN2PKMCA2FABP1HDAC1
SCHEMBL22080442 0.93 SMN1; SMN2 (0.39) SMN1; SMN2PKMCA2FABP1TDP1
SCHEMBL24257961 0.93 SMN1; SMN2 (0.39) SMN1; SMN2PKMCA2FABP1TDP1
SCHEMBL24257846 0.91 HDAC1 (0.46) SMN1; SMN2PKMCA2FABP1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3893934-B1 INSULIN CONJUGATES SANOFI SA (FR) 2025-09-10 EP disclosed
US-20220048968-A1 INSULIN CONJUGATES SANOFI (FR) 2022-02-17 US disclosed
US-20200181223-A1 INSULIN CONJUGATES SANOFI (FR) 2020-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200181223-A1 INSULIN CONJUGATES IAPP, INSR, IGF1R SMN1; SMN2 1332/4885PKM 1743/4885CA2 1521/4885
US-20220048968-A1 INSULIN CONJUGATES IAPP, INSR, IGF1R SMN1; SMN2 1332/4885PKM 1743/4885CA2 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.